Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

07. Januar 2019 06:00 ET | Quelle: OPKO Health, Inc.

OPKO Health Appoints Jon R. Cohen, M.D. Executive Chairman of BioReference Laboratories

MIAMI, Jan. 07, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the appointment of Jon R. Cohen, M.D. as Executive Chairman of BioReference Laboratories. BioReference, with...
09. November 2018 16:01 ET | Quelle: OPKO Health, Inc.

OPKO Health Reports Third Quarter 2018 Financial Results

Conference Call begins today at 4:15 p.m. Eastern Time MIAMI , Nov. 09, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) reports financial results and business highlights for the three...
08. November 2018 12:30 ET | Quelle: OPKO Health, Inc.

BioReference Laboratories Named as Preferred Laboratory with Horizon Healthcare Services

MIAMI, Nov. 08, 2018 (GLOBE NEWSWIRE) -- BioReference Laboratories, Inc. (BRL), an OPKO Health (NASDAQ: OPK) company and the third largest clinical laboratory in the United States, will remain an...
08. November 2018 09:12 ET | Quelle: OPKO Health, Inc.

OPKO Health to Announce Third Quarter 2018 Financial Results on November 9, 2018

MIAMI, Nov. 08, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to announce its operating and financial results for the three and nine months ended September 30, 2018 after the close...
04. September 2018 08:00 ET | Quelle: OPKO Health, Inc.

OPKO Initiates RAYALDEE Phase 2 Trial in Dialysis Patients

MIAMI, Sept. 04, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) has initiated a Phase 2 clinical trial to study the safety and efficacy of RAYALDEE® as a new treatment for secondary...
28. August 2018 08:00 ET | Quelle: OPKO Health, Inc.

OPKO Health’s BioReference Laboratories to Participate in the National Cancer Institute NCI-MATCH (Molecular Analysis for Therapy Choice) Phase II Clinical Trial

MIAMI, Aug. 28, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that BioReference Laboratories, Inc. (BRL), an OPKO Health company and the third largest clinical laboratory...
07. August 2018 16:05 ET | Quelle: OPKO Health, Inc.

OPKO Health Reports Second Quarter 2018 Financial Results

MIAMI, Aug. 07, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) reports financial results and business highlights for the three months ended June 30, 2018. Financial Highlights Net loss...
03. August 2018 13:29 ET | Quelle: OPKO Health, Inc.

OPKO Health Completes Enrollment in Global Phase 3 Study of Somatrogon (hGH-CTP) in Growth Hormone Deficient Children

MIAMI, Aug. 03, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) has completed enrollment in the Company’s global pivotal Phase 3 study in growth hormone deficient children, evaluating a...
02. August 2018 08:00 ET | Quelle: OPKO Health, Inc.

OPKO Health to Announce Second Quarter 2018 Financial Results on August 7, 2018

MIAMI, Aug. 02, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to announce its operating and financial results for the three and six months ended June 30, 2018 after the close of the...
16. Juli 2018 11:57 ET | Quelle: OPKO Health, Inc.

OPKO Partner Vifor Fresenius Receives Marketing Approval for RAYALDEE in Canada

MIAMI, July 16, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announced today that the Company’s partner Vifor Fresenius Medical Care Renal Pharma (VFMCRP) has received approval from...

Vorherige Seite